Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07OBG
|
||||
Former ID |
DNC007985
|
||||
Drug Name |
5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C18H16ClNO2
|
||||
Canonical SMILES |
C1=CC=C(C=C1)CCCCN2C(=O)C3=C(C2=O)C=C(C=C3)Cl
|
||||
InChI |
1S/C18H16ClNO2/c19-14-9-10-15-16(12-14)18(22)20(17(15)21)11-5-4-8-13-6-2-1-3-7-13/h1-3,6-7,9-10,12H,4-5,8,11H2
|
||||
InChIKey |
QQYWRVQHDFXEFG-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Oxysterols receptor LXR-alpha | Target Info | Inhibitor | [1] | |
KEGG Pathway | PPAR signaling pathway | ||||
Non-alcoholic fatty liver disease (NAFLD) | |||||
Hepatitis C | |||||
Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
Nuclear Receptors Meta-Pathway | |||||
PPAR Alpha Pathway | |||||
Liver X Receptor Pathway | |||||
Adipogenesis | |||||
SREBF and miR33 in cholesterol and lipid homeostasis | |||||
Nuclear Receptors | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. Epub 2007 Apr 30.Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.